Debie Y, Garcia-Fogeda I, Willem L, Roelant E, Verbruggen L, Vanhoutte G
Sci Rep. 2025; 15(1):7858.
PMID: 40050359
PMC: 11885447.
DOI: 10.1038/s41598-025-92254-8.
Aurelia L, Purcell R, Theisen R, Kelly A, Esterbauer R, Ramanathan P
Sci Adv. 2025; 11(9):eads1482.
PMID: 40009690
PMC: 11864192.
DOI: 10.1126/sciadv.ads1482.
Simonson A, Zeppa J, Bucsan A, Chao M, Pokkali S, Hopkins F
J Exp Med. 2025; 222(4).
PMID: 39912921
PMC: 11801270.
DOI: 10.1084/jem.20241571.
Vukcevic M, Despot M, Nikolic-Kokic A, Blagojevic D, Nikolic M, Banko A
Pharmaceuticals (Basel). 2025; 17(12.
PMID: 39770576
PMC: 11679259.
DOI: 10.3390/ph17121734.
Lykins W, Pollet J, White J, Keegan B, Versteeg L, Strych U
Front Immunol. 2024; 15:1480976.
PMID: 39737197
PMC: 11683073.
DOI: 10.3389/fimmu.2024.1480976.
Nonhuman primate models of pediatric viral diseases.
Vijayan K K V, De Paris K
Front Cell Infect Microbiol. 2024; 14:1493885.
PMID: 39691699
PMC: 11649651.
DOI: 10.3389/fcimb.2024.1493885.
Obtaining HBV core protein VLPs carrying SARS-CoV-2 nucleocapsid conserved fragments as vaccine candidates.
Lobaina Y, Musacchio A, Ai P, Chen R, Suzarte E, Chinea G
Virol J. 2024; 21(1):310.
PMID: 39609857
PMC: 11606075.
DOI: 10.1186/s12985-024-02583-9.
Developing Correlates of Protection for Vaccines Is Needed More than Ever-Influenza, COVID-19 and RSV Infection.
Vajo Z, Laszlofy C
Viruses. 2024; 16(11).
PMID: 39599786
PMC: 11598905.
DOI: 10.3390/v16111671.
Beyond Suppression: Peripheral T Cell Responses to Vaccination in Inflammatory Bowel Disease Patients Undergoing Anti-Tumor-Necrosis-Factor Therapy.
Qui M, Salazar E
Vaccines (Basel). 2024; 12(11).
PMID: 39591183
PMC: 11599089.
DOI: 10.3390/vaccines12111280.
Staggered immunization with mRNA vaccines encoding SARS-CoV-2 polymerase or spike antigens broadens the T cell epitope repertoire.
Abt E, Lam A, Noguchi M, Rashid K, McLaughlin J, Teng P
Proc Natl Acad Sci U S A. 2024; 121(49):e2406332121.
PMID: 39589869
PMC: 11626164.
DOI: 10.1073/pnas.2406332121.
Poor vaccine responders mask the true trend in vaccine effectiveness against progression to severe disease.
Dean N, Halloran M, Zarnitsyna V
Vaccine. 2024; 43(Pt 2):126516.
PMID: 39586191
PMC: 11822770.
DOI: 10.1016/j.vaccine.2024.126516.
Ensemble modeling of SARS-CoV-2 immune dynamics in immunologically naïve rhesus macaques predicts that potent, early innate immune responses drive viral elimination.
Byrne C, Schiffer J
Front Immunol. 2024; 15:1426016.
PMID: 39575237
PMC: 11578959.
DOI: 10.3389/fimmu.2024.1426016.
T cell epitope mapping reveals immunodominance of evolutionarily conserved regions within SARS-CoV-2 proteome.
Bozkus C, Brown M, Velazquez L, Thomas M, Wilson E, ODonnell T
bioRxiv. 2024; .
PMID: 39484455
PMC: 11527131.
DOI: 10.1101/2024.10.23.619918.
T-Cell Immune Responses to SARS-CoV-2 Infection and Vaccination.
Notarbartolo S
Vaccines (Basel). 2024; 12(10).
PMID: 39460293
PMC: 11511197.
DOI: 10.3390/vaccines12101126.
Safety and Immunogenicity Study of a Bivalent Vaccine for Combined Prophylaxis of COVID-19 and Influenza in Non-Human Primates.
Stepanova E, Isakova-Sivak I, Matyushenko V, Mezhenskaya D, Kudryavtsev I, Kostromitina A
Vaccines (Basel). 2024; 12(10).
PMID: 39460266
PMC: 11511058.
DOI: 10.3390/vaccines12101099.
Characterisation of the antibody-mediated selective pressure driving intra-host evolution of SARS-CoV-2 in prolonged infection.
Schoefbaenker M, Gunther T, Lorentzen E, Romberg M, Hennies M, Neddermeyer R
PLoS Pathog. 2024; 20(10):e1012624.
PMID: 39405332
PMC: 11508484.
DOI: 10.1371/journal.ppat.1012624.
Three doses of Sars-CoV-2 mRNA vaccine in older adults result in similar antibody responses but reduced cellular cytokine responses relative to younger adults.
Bredholt G, Saevik M, Soyland H, Ueland T, Zhou F, Pathirana R
Vaccine X. 2024; 20:100564.
PMID: 39403561
PMC: 11472110.
DOI: 10.1016/j.jvacx.2024.100564.
Meeting Report From "Correlates of Protection for Next Generation Influenza Vaccines: Lessons Learned From the COVID-19 Pandemic".
Krammer F, Katz J, Engelhardt O, Post D, Roberts P, Sullivan S
Influenza Other Respir Viruses. 2024; 18(10):e13314.
PMID: 39380156
PMC: 11461279.
DOI: 10.1111/irv.13314.
Studying the Humoral Response against SARS-CoV-2 in Cuban COVID-19 Recovered Patients.
Orosa Vazquez I, Diaz M, Zuniga Rosales Y, Amada K, Chang J, Relova Hernandez E
J Immunol Res. 2024; 2024:7112940.
PMID: 39359695
PMC: 11446615.
DOI: 10.1155/2024/7112940.
Design, Immunogenicity and Preclinical Efficacy of the ChAdOx1.COVconsv12 Pan-Sarbecovirus T-Cell Vaccine.
Wee E, Kempster S, Ferguson D, Hall J, Ham C, Morris S
Vaccines (Basel). 2024; 12(9).
PMID: 39339997
PMC: 11436245.
DOI: 10.3390/vaccines12090965.